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ORIGINAL WORK
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Abstract
Background/Objective: Stress-related mucosal bleeding (SRMB) occurs in approximately 2–4% of critically ill
patients. Patients with aneurysmal subarachnoid hemorrhage (aSAH) have a (diffuse) space-occupying lesion, are criti‑
cally ill, often require mechanical ventilation, and frequently receive anticoagulation or antiplatelet therapy after aneu‑
rysm embolization, all of which may be risk factors for SRMB. However, no studies have evaluated SRMB in patients
with aSAH. Aims of the study were to determine the incidence of SRMB in aSAH patients, evaluate the effect of acid
suppression on SRMB, and identify specific risk factors for SRMB.
Methods: This was a multicenter, retrospective, observational study conducted across 17 centers. Each center
reviewed up to 50 of the most recent cases of aSAH. Patients with length of stay (LOS) < 48 h or active GI bleeding on
admission were excluded. Variables related to demographics, aSAH severity, gastrointestinal (GI) bleeding, provision
of SRMB prophylaxis, adverse events, intensive care unit (ICU), and hospital LOS were collected for the first 21 days
of admission or until hospital discharge, whichever came first. Descriptive statistics were used to analyze the data. A
multivariate logistic regression modeling was utilized to examine the relationship between specific risk factors and
the incidence of clinically important GI bleeding in patients with aSAH.
Results: A total of 627 patients were included. The overall incidence of clinically important GI bleeding was 4.9%. Of
the patients with clinically important GI bleeding, 19 (61%) received pharmacologic prophylaxis prior to evidence of
GI bleeding, while 12 (39%) were not on pharmacologic prophylaxis at the onset of GI bleeding. Patients who received
an acid suppressant agent were less likely to experience GI bleeding than patients who did not receive pharmaco‑
logic prophylaxis prior to evidence of bleeding (OR 0.39, 95% CI 0.18–0.83). The multivariate regression analysis identi‑
fied any instance of elevated intracranial pressure, creatinine clearance < 60 ml/min and the incidence of cerebral
vasospasm as specific risk factors associated with GI bleeding. Cerebral vasospasm has not previously been described
as a risk for GI bleeding (OR 2.5 95% CI 1.09–5.79).
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Conclusions: Clinically important GI bleeding occurred in 4.9% of patients with aSAH, similar to the general critical
care population. Risk factors associated with GI bleeding were prolonged mechanical ventilation (> 48 h), creatinine
clearance < 60 ml/min, presence of coagulopathy, elevation of intracranial pressure, and cerebral vasospasm. Further
prospective research is needed to confirm this observation within this patient population.
Keywords: Stress ulcer prophylaxis, Acid-suppressive therapy, Subarachnoid hemorrhage, Cerebral vasospasm,
Proton pump inhibitors, Histamine-2-receptor antagonists, Gastrointestinal hemorrhage, Neurocritical care

Introduction
Stress-related mucosal bleeding (SRMB) occurs in
approximately 2–4% of critically ill patients receiving
stress ulcer prophylaxis. Clinically important gastrointestinal (GI) bleeding increases morbidity and mortality
[1]. Neurocritical care patients are often thought to be at
increased risk of stress-related bleeding due to increases
in vagal tone and gastric acid secretion, dating back to
observations by Harvey Cushing in the 1930s [2, 3]. The
majority of the landmark trials in this area excluded
‘brain injury’ patients or included a small number of neurocritical care patients (without specifying the diagnosis)
[4].
Few clinical trials have evaluated the incidence of clinically important GI bleeding or the efficacy of stress ulcer
prophylaxis in neurocritical care patients and none have
evaluated this complication in aneurysmal subarachnoid
hemorrhage (aSAH) patients [5, 6]. Patients with aSAH
may exhibit all of the classic risk factors for clinically
important GI bleeding such as hypotension, increased
intracranial pressure, prolonged mechanical ventilation
and coagulopathy [7–10]. In addition, these patients may
also receive antiplatelet or anticoagulant agents as an
aspect of their aneurysm treatment [11–13]. One retrospective study of patients with aSAH demonstrated that
approximately 4% of aSAH patients exhibited GI bleeding, though the definition of bleeding was not specified
[7]. Additionally, patients with aSAH have a risk of cerebral vasospasm which can increase intracranial pressure,
necessitate the use of vasopressor agents, and is associated with a systemic inflammatory response, all of which
we hypothesize increase the risk of clinically important
GI bleeding.
Studies investigating critically ill patients with risk
factors for clinically important GI bleeding suggest that
bleeding occurs in 1.7–6.8% of patients receiving a histamine-2 receptor antagonist (H2RA) for prophylaxis [4, 6,
14]. Similarly, the incidence of bleeding in those receiving other prophylactic agents is also within this range,
with clinically significant bleeding occurring in 4.5% and
3.8% of patients receiving proton pump inhibitors (PPI)
and sucralfate, respectively [4, 6]. Smaller clinical investigations evaluating the GI bleeding rate in patients specifically with intracranial hemorrhage suggest a higher

incidence, despite the use of acid-suppressing agents
(11–27.8%) [5, 15]. The risk of pneumonia (approximately
20% incidence) or other complications such as Clostridium difficile diarrhea with acid suppressive agents has
been described in other studies [4, 5, 14]. Patients with
aSAH may require prolonged mechanical ventilation,
which increases the risk of pneumonia in many of these
studies [9, 10]. Additionally, most patients with aSAH
also exhibit some degree of immune dysfunction further
increasing the risk of infection [7, 16].
No human studies to date have specifically included
or described the rate of clinically important bleeding in
patients with aSAH nor have any studies evaluated the
efficacy or safety of acid suppressive therapies in this
unique patient population [17, 18]. This study was conducted to evaluate the following related to clinically
important GI bleeding in aSAH patients: the overall incidence, the effect of acid suppression on the incidence,
and specific risk factors. The primary objective of the
study was to determine the incidence of clinically important GI bleeding in patients with aSAH. Secondary objectives included evaluating the effect of prophylaxis of
clinically important GI bleeding in patients with aSAH,
identifying specific risk factors for clinically important
GI bleeding in this patient population, and assessing incidence of adverse effects, specifically diagnosis of C. difficile and diagnosis of pneumonia during hospital stay.

Methods
This was a multicenter, retrospective, observational study
conducted across 17 academic medical centers in North
America. Each center reviewed up to 50 of the most
recent cases of aSAH based on the corresponding ICD-9
code (430) or ICD-10 code (160.0–160.9). Study data
were collected and managed using REDCap electronic
data capture tools at University of Kentucky HealthCare
[19]. Patients were included if they were between the
ages of 18 and 85 years and admitted for acute, nontraumatic SAH between the dates of January 1, 2013 and June
30, 2017 in reverse chronological order. Patients were
excluded if there was evidence of active GI bleeding on
admission, if hospital length of stay was less than 48 h, or
if significant gaps in documentation related to data collection were present. Each center obtained approval from

their local institutional review board (IRB) and was subject to regulation by the primary governing IRB.
Variables related to demographics, aSAH severity, GI
bleeding, provision of SRMB prophylaxis, infectionrelated adverse events, intensive care unit (ICU), and
hospital length of stay were collected for the first 21 days
of admission or until hospital discharge, whichever came
first. For the purpose of this analysis, all available histamine-2 receptor antagonists were combined into the
same category (“H2RAs”). Similarly, all commercially
available proton pump inhibitors were combined into the
same category (“PPIs”). Clinically important GI bleeding
was defined as any instance of the following within 24 h
of reported GI bleeding: blood transfusion requirement,
hemoglobin reduction of 2 gm/dl or greater, or abrupt
systolic blood pressure reduction of ≥ 20 mmHg. Renal
dysfunction was defined as an estimated creatinine clearance less than 60 mL/min (by eGFR or Cockcroft-Gault)
and coagulopathy was defined as an INR greater than
1.5. Cerebral vasospasm was defined as receiving intraarterial treatment by calcium channel blockers or other
rescue agents, by radiographic evidence (described during digital subtraction angiography), or by a Lindegaard
ratio of > 3. Intensity of anticoagulation was collected,
including administration of anti-platelet agents (aspirin, clopidogrel, ticagrelor, prasugrel), prophylaxis of
venous thromboembolism (VTE), and therapeutic anticoagulation. Other data collected included the presence
of enteral or oral nutrition, diagnosis of C. difficile any
time during hospital stay, and diagnosis of pneumonia
any time during hospital stay, including pathogen cultured, if applicable. For this study, a practical definition
of pneumonia was employed due to the retrospective
nature of the study. Patients were categorized as having
been treated for pneumonia if: [1] the patient had BAL,
PAL, or sputum cultures and the presence of antibiotics,
or [2] a review of progress notes stating a pneumonia was
suspected for which antibiotics were initiated. If cultures
were obtained, centers provided the pathogen cultured
during data collection. Missing data were addressed
using casewise deletion.
The statistical analysis consisted of descriptive statistics for the population demographics. A two-tailed Students t test or Chi Squared analysis was used to compare
demographic characteristics, as appropriate for the type
of data. In order to have 80% power, assuming a clinically
important GI bleeding rate of 4%, it was estimated that
a total number of 352 patients in the two cohorts would
be required to detect a 1% incidence of clinically important GI bleeding between treatment groups. The incidence of clinically important bleeding, pneumonia, and
C. difficile diarrhea was evaluated using relevant tests
such as Chi Squared or ANOVA. Bivariate analysis was

generated using IBM SPSS Statistics (v23, Armonk, NY).
A multivariate logistic regression modeling was utilized
to examine the relationship between specific risk factors
and the incidence of clinically important GI bleeding in
patients with aSAH. The full model included the main
effects (age, gender, need for mechanical ventilation,
study site, and numerous other variables) and two-way
interactions between Hunt-Hess score and vasospasm,
vasospasm and age, and creatinine clearance and age.
An additional analysis of patients from each cohort (with
and without GI bleeding) was also performed by matching patients 1:1 based on Hunt and Hess score, discharge
outcome, age (within 10 years), and presence of the following risk factors: mechanical ventilation, vasospasm,
no stress ulcer prophylaxis, ICP > 20, and renal impairment (CrCl < 60 mL/min). Level of significance was set
at a p-value < 0.05. The data analysis was generated using
SAS software (v9.4, Cary, NC).

Results
A total of 627 patients were included in the study population. All patients were admitted for a spontaneous,
nontraumatic aSAH. Two cohorts, those with evidence
of clinically important GI bleeding and those with no GI
bleeding, were compared to evaluate characteristics associated with bleeding. The overall incidence of clinically
important GI bleeding was 4.9%. Several clinical characteristics were significantly different in the demographics
of the two cohorts (Table 1). Of note, patients who had
evidence of GI bleeding more frequently had a prior history of GI bleeding, more severe presentation of their
aSAH (based on Hunt-Hess score), a higher incidence of
cerebral vasospasm, and a longer length of stay (Table 1).
At least one dose of corticosteroid was administered in
47.8% of patients, but the use was not different between
the two cohorts. The majority of patients (72.5%) underwent aneurysm embolization during the study period.
A variety of prophylaxis agents were used across the
study population in the majority of patients, with many
patients receiving both an H2RA and a PPI during the
study period (not usually concomitantly, Table 1). There
was no difference in the rate of use of one class of agents
over the other. One hundred eighteen (20%) patients with
no GI bleeding received no pharmacologic prophylaxis
for the duration of the study period. Of the patients with
clinically important GI bleeding, 19 (61%) received pharmacologic prophylaxis prior to evidence of GI bleeding,
while 12 (39%) were not on pharmacologic prophylaxis at
the onset of GI bleeding. Overall, patients who received
an acid suppressant agent were less likely to experience
GI bleeding than patients who did not receive pharmacologic prophylaxis prior to evidence of bleeding (OR 0.39,
95% confidence interval 0.18–0.83). This suggests the

Table 1 Patient demographics
Characteristic

GI bleed (n = 31)

No GI bleed (n = 596)

p-value

Age, years

54.6 (10.4)

56.8 (13.1)

0.363

Female sex

23 (74.2)

379 (63.6)

0.230

History of GI bleed

3 (9.7)

10 (1.7)

0.002

Hunt & Hess Score

3 [1–5]

2 [1–5]

0.038

Fisher Score

4 [1–4]

3 [1–4]

0.038

Coil

18 (58.1)

253 (42.4)

Clip

5 (16.1)

134 (22.5)

Other

1 (3.2)

43 (7.2)

None

7 (22.6)

166 (27.9)

Aneurysm intervention

0.367

SRMB prophylaxis
PPI*

23 (74%)**

215 (36%)

H2RA*

25 (81%)**

339 (57%)

< 0.0001
0.009

No agent

6 (19.4%)**

118 (20%)

0.952

Corticosteroid use

12 (38.7)

288 (48.3%)

0.296

Length of stay (days)

20 (5-81)

15 (2-175)

0.004

ICU length of stay (days)

17 (5-44)

12 (0-82)

0.005

GI = gastrointestinal; H2RA = histamine-2 receptor antagonist; ICU = intensive care unit; PPI = proton pump inhibitor; SRMB = Stress related mucosal bleeding
Note Data reported as N (%) or median (interquartile range)

*some patients received a combination of PPI and H2RA during their admission
**number of patients reported with PPI, H2RA, or no prophylaxis prior to GI bleeding episode

potential for a protective effect of pharmacologic prophylaxis for the incidence of clinically important GI bleeding.
Bivariate analyses and multivariate regression analyses
were performed to identify factors associated with GI
bleeding. Variables identified as significant in the bivariate analysis along with Hunt-Hess score, age, gender,
and study site were included in the multivariate analysis. Classic SRMB factors such as prolonged mechanical
ventilation, any creatinine clearance < 60 ml/min, and
coagulopathy were more prevalent in the GI bleed cohort
(Table 2). Elevated intracranial pressure was also more
prevalent in the GI bleed cohort (p = 0.001), which links
well with the other classic risk factor for SRMB, traumatic brain injury. The multivariate regression analysis
identified any instance of elevated intracranial pressure,

creatinine clearance < 60 ml/min and the incidence of
cerebral vasospasm as specific risk factors associated
with GI bleeding (Table 3). Patients with any incidence of
cerebral vasospasm were 2.5 times more likely to experience GI bleeding compared to patients without vasospasm. None of the two-way interactions to evaluate the
interplay between potential risk factors such as aSAH
severity (Hunt-Hess score) and vasospasm, vasospasm
and age, and Hunt-Hess score and intracranial pressure
were significant for interaction to the model.
A full accounting of all adverse events of the acid suppressive agents was not evaluated due to the retrospective design of the study. The diagnosis of pneumonia
at any point in the stay was noted in 23.4% of patients
overall (n =147). Of the patients with pneumonia, 46.9%

Table 2 Clinically important GI bleeding Risk Factors
GI bleed (n = 31)

No GI bleed (n = 596)

p-value

Mechanical ventilation

25 (81.6%)

349 (58.6%)

0.015

Coagulopathy (INR > 1.5)

5 (16.1%)

23 (3.9%)

0.001

Any corticosteroids

12 (38.7%)

288 (48.3%)

0.296

Any ICP > 20

17 (54.8%)

170 (28.5%)

0.001

Any ClCr < 60 ml/min

14 (45.2%)

93 (15.6%)

0.0002

Cerebral vasospasm

21 (67.7)

267 (44.8)

0.012

Note Data reported as N (%)
ClCr = creatinine clearance; GI = gastrointestinal; ICP = intracranial pressure

Table 3 Multivariate analysis of factors related to clinically
important GI bleeding
Characteristic

Odds ratio

95%
Confidence
interval

p-value

β

Any ICP > 20

2.27

1.03-4.97

0.041

0.82

Any ClCr < 60 ml/min

5.05

2.31-11.03

< 0.0001

1.62

Cerebral vasospasm

2.51

1.09-5.79

Intercept

0.0314

0.92
− 4.30

ClCr = creatinine clearance; GI = gastrointestinal; ICP = intracranial pressure

(n =69) of the patients received a PPI at any point in their
stay compared to 35.2% (n =169) of those who did not
receive a PPI (p =0.01). H2RA administration occurred
in 69.4% (n =102) at any point in their stay of those with
pneumonia compared to 54.6% (n =262) of those who
did not (p =0.001). The overall rate of Clostridium difficile diarrhea was 2.4% (n =15). Two of the fifteen patients
received a PPI early in their admission (one for the entire
stay, the other for 6 of the first 7 days of the admission,
then no PPI thereafter). The other thirteen patients with
Clostridium difficile diarrhea received an H2RA early in
their admission for variable durations.

Discussion
This study is the first to evaluate the GI bleeding rate in
patients with aSAH. The GI bleeding rate (4.9%) is within
the range typically reported for the general critical care
population on pharmacologic prophylaxis (1.7–6.8%) [4,
6, 14]. Several of the classic risk factors for SRMB such
as prolonged mechanical ventilation (> 48 h), creatinine
clearance < 60 ml/min, presence of coagulopathy, and
elevation of intracranial pressure were affirmed as risk
factors in the aSAH population [1, 2]. The occurrence of
cerebral vasospasm was also significantly associated with
clinically important GI bleeding. This is the first time that
cerebral vasospasm has been implicated as a risk for GI
bleeding. Patients who did not receive pharmacologic
prophylaxis were more likely to experience clinically
important GI bleeding, a finding that is not surprising
given the high rate of GI bleeding in the current cohort.
This result supports the notion that aSAH patients are
at high risk of clinically important GI bleeding and the
potential protective effect of pharmacologic prophylaxis.
Conversely, the use of acid suppressive agents was associated with an increased rate of pneumonia.
Patients with aSAH exhibit several characteristics that
are unique among neurocritical care patients. First, many
of these patients are awake and oriented despite the presence of subarachnoid blood. As such, many patients do

not require endotracheal intubation (only 59.6% of the
current cohort were intubated at any point aside from
temporary intubation for necessary procedures). Second, patients with lower grade aSAH are usually able to
eat a regular diet by mouth and do not require enteral or
parenteral nutrition. In short, patients in the intensive
care unit who are neurologically oriented and conversant, while tolerating a regular diet are not typically the
patients clinicians feel are at risk for SRMB. Coinciding
with this perceived lack of risk, over 20% of the patients
included in this study did not receive primary pharmacologic prophylaxis for clinically important GI bleeding.
Reasons for omitting this therapy were not recorded.
However, with the advent of standardized order sets in
electronic medical records and the ubiquity of mnemonics to remind clinicians to add acid suppressant agents in
critically ill patients, it is likely that a conscious decision
was made to omit prophylaxis due to the perceived low
risk of SRMB in patients with aSAH without ‘conventional’ risk factors [20].
The presence of cerebral vasospasm appears to be a
substantial risk for clinically important GI bleeding in
patients with aSAH. The etiology of cerebral vasospasm
appears to be multi-factorial and is certainly associated
with the presence of blood in the subarachnoid space.
The physical irritation of the blood on the meninges, liberation of hemoglobin and iron from acute hemolysis,
inflammatory mediators aimed at removing the noxious
stimulus, increased oxidative stress, increases in endogenous vasoconstrictors (e.g., endothelin) and scavenging
of nitric oxide may all play a role in the development of
cerebral vasospasm [21]. It is unknown whether any of
these factors may directly increase the risk of clinically
important GI bleeding. Several recent studies have suggested a link between systemic inflammation and cerebral vasospasm (one begets the other in both directions)
[21]. An increase in systemic inflammation similar to
the physiologic response to sepsis could be an important
factor in increasing the risk of clinically important GI
bleeding in patients with aSAH and cerebral vasospasm.
Furthermore, red blood cell transfusions are also associated with cerebral vasospasm, which may create a cyclic
problem for patients with aSAH and clinically relevant
GI bleeding [22]. Finally, the presence of vasospasm is
associated with high sympathetic tone, which may also
affect gastric motility, acid secretion, and maintenance
of the gastric mucosa [23, 24]. Published studies on this
dynamic specifically in subarachnoid hemorrhage are not
available, though it has been well-demonstrated that high
sympathetic tone or high amounts of exogenous catecholamines can reduce splanchnic perfusion thereby increasing the risk of stress-related mucosal damage [25–27].
The majority of the patients who experienced clinically

important GI bleeding and vasospasm experienced
vasospasm before bleeding. However, it was not possible to evaluate causation in these instances nor in the
instances where bleeding occurred prior to documentation of vasospasm, as the impact of evolving vasospasm
on GI bleeding is not well-described. Future translational
work aimed at further clarifying the relationship of these
factors is necessary.
This study has several strengths which increase our
confidence that these findings are not by chance. First,
patients were included from 17 different hospitals in
North America, which increases the real-life heterogeneous treatment practices that comes with evaluating
patients in so many different facilities. Due to the relative
ubiquity of the use of pharmacologic prophylaxis seen in
this cohort, it is unlikely that institution-specific variations in care contributed to the development of GI bleeding as might be seen with a single center study. Second,
the data collection related to potential risk factors was
extensive. aSAH patients often have a prolonged intensive care unit stay due to the risk of vasospasm over the
first one to two weeks after ictus, allowing for a wealth of
data on most patients to assess risk factors for bleeding.
Finally, the classic risk factors for SRMB were confirmed
with the current study (mechanical ventilation (> 48 h),
creatinine clearance < 60 ml/min, presence of coagulopathy, and elevation of intracranial pressure), which suggests the cohort is reflective of a critically ill population
overall.
Several issues which may limit the interpretation of
this data merit acknowledgement. The retrospective
design limited the opportunity to account for all of the
potential risks for clinically important GI bleeding.
For instance, the presence of shock and hypotension
is also well-associated with SRMB. We did not collect information on shock or hypotension in the current cohort. Patients with aSAH infrequently present
with hypotension, but in a small percent of patients,
myocardial stunning may result in shock early in the
course of illness [28]. Iatrogenic hypotension related
to acute blood pressure changes prior to securing the
aneurysm or related to nimodipine use may have also
occurred, which was not accounted for. Esophagogastroduodenoscopy was not routinely performed in the
patients included in this study, as prospective screening for SRMB is not typical without clinical suspicion.
Thus, the true incidence of SRMB (as opposed to clinically important GI bleeding) in this population remains
undefined. Some severity scores were not available in
the medical record, so these patients were not included
when evaluating the effect of aSAH severity on the
risk of clinically important GI bleeding. We collected
information on enteral nutrition, but were not able to

consistently assess the amount of caloric intake nor
was the extent of oral diet evaluated due to the nature
of the retrospective design and missing documentation. Provision of enteral nutrition may be a protective
factor for SRMB, but we were unable to include this in
our analysis [29]. Finally, we collected data on the incidence of pneumonia and C. difficile diarrhea, but other
adverse events associated with acid suppressant agents
may have occurred and were not accounted for. Many
of these potential sources of bias would be neutralized
by conducting a prospective trial evaluating the impact
of pharmacologic prophylaxis on GI bleeding in this
population. It seems unlikely this will occur given the
niche population of aSAH and the sample size required.

Conclusion
Patients with aSAH had an incidence of GI bleeding of 4.9% in this cohort. Risk factors associated with
GI bleeding were prolonged mechanical ventilation
(> 48 h), creatinine clearance < 60 ml/min, presence of
coagulopathy, elevation of intracranial pressure, and
cerebral vasospasm. This is the first study to identify
cerebral vasospasm as a risk factor for GI bleeding,
increasing the risk by 2.5 fold. Given the high rate of
GI bleeding and the potential protective effect of pharmacologic prophylaxis, the results of this study suggest
that clinicians should consider aSAH as high-risk for
clinically important GI bleeding and evaluate prescription of prophylaxis of SRMB in patients with aSAH,
particularly through the vasospasm window. These
results warrant further exploration within robust randomized controlled trials.
Electronic supplementary material
The online version of this article (https://doi.org/10.1007/s12028-020-01137-5)
contains supplementary material, which is available to authorized users.
Author details
1
University of Kentucky HealthCare, Lexington, USA. 2 Massachusetts General
Hospital, Boston, USA. 3 Saint Luke’s Health System-Kansas City, Kansas City,
USA. 4 Virginia Commonwealth University, Richmond, USA. 5 Mayo Clinic,
Rochester, USA. 6 Hospital of the University of Pennsylvania, Philadelphia,
USA. 7 University of Michigan Hospital, Ann Arbor, USA. 8 Henry Ford Hospital,
Detroit, USA. 9 Cedars-Sinai Hospital, Los Angeles, USA. 10 Tampa General
Hospital, Tampa, USA. 11 Lifespan/Rhode Island Hospital, Providence, USA.
12
University of Alberta, Edmonton, Canada. 13 Ohio State Wexner Medical
Center, Columbus, USA. 14 Edward-Elmhurst Hospital, Chicago, USA. 15 Rush
University Medical Center, Chicago, USA. 16 Novant Health, Winston‑Salem,
USA. 17 University Hospitals, Shaker Heights, USA. 18 University of Kentucky
College of Pharmacy, Lexington, USA.
Author Contributions
DA and AC primarily conceived the study design, but all authors had input
on study design and execution. Data analysis was performed primarily by DA,
AS, and AMC; all authors had input on data interpretation. DA, AS, and AMC
primarily wrote the manuscript, but all authors were able to review and revise
ad lib. All authors provided a final review and approval of the manuscript.

Source of Support
The study was not funded. Investigators used REDCap for data entry (NIH
CTSA UL1TR000117).
Conflict of interest
No pertinent conflicts of interest were reported.
Ethical Approval
The study was approved via expedited review by the University of Kentucky
IRB.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 9 March 2020 Accepted: 15 October 2020

References
1. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleed‑
ing in critically ill patients Canadian Critical Care Trials Group. N Engl J
Med. 1994;330(6):377–81.
2. Lu WY, Rhoney DH, Boling WB, Johnson JD, Smith TC. A review of stress
ulcer prophylaxis in the neurosurgical intensive care unit. Neurosurgery.
1997;41(2):416–25 (discussion 425–416).
3. Cushing H. Peptic ulcer and the interbrain. Surg Gynecol Obstet.
1932;55:1–34.
4. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ran‑
itidine for the prevention of upper gastrointestinal bleeding in patients
requiring mechanical ventilation. N Engl J Med. 1998;338(12):791–7.
5. Liu BL, Li B, Zhang X, et al. A randomized controlled study comparing
omeprazole and cimetidine for the prophylaxis of stress-related upper
gastrointestinal bleeding in patients with intracerebral hemorrhage. J
Neurosurg. 2013;118(1):115–20.
6. Conrad SA, Gabrielli A, Margolis B, et al. Randomized, double-blind
comparison of immediate-release omeprazole oral suspension versus
intravenous cimetidine for the prevention of upper gastrointestinal
bleeding in critically ill patients. Crit Care Med. 2005;33(4):760–5.
7. Wartenberg KE, Schmidt JM, Claassen J, et al. Impact of medical com‑
plications on outcome after subarachnoid hemorrhage. Crit Care Med.
2006;34(3):617–23 (quiz 624).
8. Heuer GG, Smith MJ, Elliott JP, Winn HR, LeRoux PD. Relationship between
intracranial pressure and other clinical variables in patients with aneurys‑
mal subarachnoid hemorrhage. J Neurosurg. 2004;101(3):408–16.
9. Frontera JA, Fernandez A, Schmidt JM, et al. Impact of nosocomial
infectious complications after subarachnoid hemorrhage. Neurosurgery.
2008;62(1):80–7 (discussion 87).
10. Cinotti R, Dordonnat-Moynard A, Feuillet F, et al. Risk factors and
pathogens involved in early ventilator-acquired pneumonia in patients
with severe subarachnoid hemorrhage. Eur J Clin Microbiol Infect Dis.
2014;33(5):823–30.
11. Kim KS, Fraser JF, Grupke S, Cook AM. Management of antiplatelet ther‑
apy in patients undergoing neuroendovascular procedures. J Neurosurg.
2018;129(4):890–905.

12. James RF, Khattar NK, Aljuboori ZS, et al. Continuous infusion of low-dose
unfractionated heparin after aneurysmal subarachnoid hemorrhage: a
preliminary study of cognitive outcomes. J Neurosurg. 2018;130:1–8.
13. Khattar NK, Bak E, White AC, James RF. Heparin treatment in aneurysmal
subarachnoid hemorrhage: a review of human studies. Acta Neurochir
Suppl. 2020;127:15–9.
14. MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists
vs proton pump inhibitors on gastrointestinal tract hemorrhage and
infectious complications in the intensive care unit. JAMA Int Med.
2014;174(4):564–74.
15. Misra UK, Kalita J, Pandey S, Mandal SK, Srivastava MA. randomized
placebo controlled trial of ranitidine versus sucralfate in patients with
spontaneous intracerebral hemorrhage for prevention of gastric hemor‑
rhage. J Neurol Sci. 2005;239(1):5–10.
16. Sarrafzadeh A, Schlenk F, Meisel A, Dreier J, Vajkoczy P, Meisel C. Immu‑
nodepression after aneurysmal subarachnoid hemorrhage. Stroke.
2011;42(1):53–8.
17. Schirmer CM, Kornbluth J, Heilman CB, Bhardwaj A. Gastrointestinal
prophylaxis in neurocritical care. Neurocrit Care. 2012;16(1):184–93.
18. Tsuchiya J, Ito Y, Hino T, Ohashi H, Kunieda T, Sakata K. Stress ulcer
accompanying subarachnoid hemorrhage–a new rat model. Jpn J Surg.
1983;13(4):373–80.
19. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
electronic data capture (REDCap)–a metadata-driven methodology and
workflow process for providing translational research informatics sup‑
port. J Biomed Inform. 2009;42(2):377–81.
20. Vincent JL. Give your patient a fast hug (at least) once a day. Crit Care
Med. 2005;33(6):1225–9.
21. Pradilla G, Chaichana KL, Hoang S, Huang J, Tamargo RJ. Inflammation
and cerebral vasospasm after subarachnoid hemorrhage. Neurosurg Clin
N Am. 2010;21(2):365–79.
22. Smith MJ, Le Roux PD, Elliott JP, Winn HR. Blood transfusion and increased
risk for vasospasm and poor outcome after subarachnoid hemorrhage. J
Neurosurg. 2004;101(1):1–7.
23. Ogura T, Satoh A, Ooigawa H, et al. Characteristics and prognostic value
of acute catecholamine surge in patients with aneurysmal subarachnoid
hemorrhage. Neurol Res. 2012;34(5):484–90.
24. Moussouttas M, Lai EW, Huynh TT, et al. Association between acute
sympathetic response, early onset vasospasm, and delayed vasospasm
following spontaneous subarachnoid hemorrhage. J Clin Neurosci.
2014;21(2):256–62.
25. Dive A, Foret F, Jamart J, Bulpa P, Installe E. Effect of dopamine on
gastrointestinal motility during critical illness. Intensive Care Med.
2000;26:901–7.
26. Steinberg K. Stress-related mucosal disease in the critically ill patient: risk
factors and strategies to prevent stress-related bleeding in the intensive
care unit. Crit Care Med. 2002;30(6):S362–4.
27. Naredi S, Lambert G, Eden E, et al. Increased sympathetic nervous activ‑
ity in patients with nontraumatic subarachnoid hemorrhage. Stroke.
2000;31(4):901–6.
28. Hessel EA. 2nd the brain and the heart. Anesth Analg. 2006;103(3):522–6.
29. Huang HB, Jiang W, Wang CY, Qin HY, Du B. Stress ulcer prophylaxis in
intensive care unit patients receiving enteral nutrition: a systematic
review and meta-analysis. Crit Care. 2018;22(1):20.

